A detailed history of Redmond Asset Management, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Redmond Asset Management, LLC holds 36,157 shares of ANVS stock, worth $201,032. This represents 0.14% of its overall portfolio holdings.

Number of Shares
36,157
Previous 34,080 6.09%
Holding current value
$201,032
Previous $637,000 32.5%
% of portfolio
0.14%
Previous 0.21%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$8.47 - $18.93 $17,592 - $39,317
2,077 Added 6.09%
36,157 $430,000
Q3 2023

Oct 24, 2023

BUY
$9.37 - $14.12 $655 - $988
70 Added 0.21%
34,080 $323,000
Q4 2022

Feb 06, 2023

BUY
$10.99 - $13.55 $373,769 - $460,835
34,010 New
34,010 $456,000
Q4 2021

Feb 04, 2022

SELL
$17.58 - $37.67 $138,495 - $296,764
-7,878 Closed
0 $0
Q3 2021

Oct 22, 2021

BUY
$30.95 - $120.97 $3,961 - $15,484
128 Added 1.65%
7,878 $250,000
Q2 2021

Aug 11, 2021

BUY
$21.55 - $96.1 $167,012 - $744,775
7,750 New
7,750 $663,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $45.4M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Redmond Asset Management, LLC Portfolio

Follow Redmond Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmond Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmond Asset Management, LLC with notifications on news.